Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience
Reid W. Merryman(Harvard University), Eric D. Jacobsen(Dana-Farber Cancer Institute), Robert Redd(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Amanda F. Cashen(Washington University in St. Louis), Robin Joyce(Beth Israel Deaconess Medical Center), Caron A. Jacobson(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Natasha Edwin(Washington University in St. Louis), Philippe Armand(Harvard University), Heather A. Jacene(Brigham and Women's Hospital), Matthew Chase(Brigham and Women's Hospital), Matthew S. Davids(Dana-Farber Cancer Institute), Brad S. Kahl(UW Health University Hospital), Nancy L. Bartlett(Washington University in St. Louis), Armin Ghobadi(Washington University in St. Louis), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Mehta-Shah Neha(Washington University in St. Louis), Jad Bsat(Dana-Farber Cancer Institute)
Cited by 7
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k